Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.
Kandioler D, Schoppmann SF, Zwrtek R, Kappel S, Wolf B, Mittlböck M, Kührer I, Hejna M, Pluschnig U, Ba-Ssalamah A, Wrba F, Zacherl J. Kandioler D, et al. Among authors: kappel s. J Thorac Cardiovasc Surg. 2014 Nov;148(5):2280-6. doi: 10.1016/j.jtcvs.2014.06.079. Epub 2014 Jul 22. J Thorac Cardiovasc Surg. 2014. PMID: 25135238 Free article. Clinical Trial.
TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer.
Kandioler D, Zwrtek R, Ludwig C, Janschek E, Ploner M, Hofbauer F, Kührer I, Kappel S, Wrba F, Horvath M, Karner J, Renner K, Bergmann M, Karner-Hanusch J, Pötter R, Jakesz R, Teleky B, Herbst F. Kandioler D, et al. Among authors: kappel s. Ann Surg. 2002 Apr;235(4):493-8. doi: 10.1097/00000658-200204000-00006. Ann Surg. 2002. PMID: 11923604 Free PMC article.
Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer.
Kandioler D, Stamatis G, Eberhardt W, Kappel S, Zöchbauer-Müller S, Kührer I, Mittlböck M, Zwrtek R, Aigner C, Bichler C, Tichy V, Hudec M, Bachleitner T, End A, Müller MR, Roth E, Klepetko W. Kandioler D, et al. Among authors: kappel s. J Thorac Cardiovasc Surg. 2008 May;135(5):1036-41. doi: 10.1016/j.jtcvs.2007.10.072. J Thorac Cardiovasc Surg. 2008. PMID: 18455581 Free article.
TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients.
Kandioler D, Mittlböck M, Kappel S, Puhalla H, Herbst F, Langner C, Wolf B, Tschmelitsch J, Schippinger W, Steger G, Hofbauer F, Samonigg H, Gnant M, Teleky B, Kührer I; p53 Research Group and the Austrian Breast and Colorectal Study Group (ABCSG). Kandioler D, et al. Among authors: kappel s. EBioMedicine. 2015 Jun 8;2(8):825-30. doi: 10.1016/j.ebiom.2015.06.003. eCollection 2015 Aug. EBioMedicine. 2015. PMID: 26425688 Free PMC article. Clinical Trial.
Assessing the TP53 marker type in patients treated with or without neoadjuvant chemotherapy for resectable colorectal liver metastases: a p53 Research Group study.
Pilat N, Grünberger T, Längle F, Mittlböck M, Perisanidis B, Kappel S, Wolf B, Starlinger P, Kührer I, Mühlbacher F, Kandioler D. Pilat N, et al. Among authors: kappel s. Eur J Surg Oncol. 2015 May;41(5):683-9. doi: 10.1016/j.ejso.2015.02.003. Epub 2015 Feb 25. Eur J Surg Oncol. 2015. PMID: 25773284
The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer.
Kandioler-Eckersberger D, Kappel S, Mittlböck M, Dekan G, Ludwig C, Janschek E, Pirker R, Wolner E, Eckersberger F. Kandioler-Eckersberger D, et al. Among authors: kappel s. J Thorac Cardiovasc Surg. 1999 Apr;117(4):744-50. doi: 10.1016/S0022-5223(99)70295-3. J Thorac Cardiovasc Surg. 1999. PMID: 10096970 Free article.
152 results